CU23804B7 - Compuesto [1,2,3]-benzotriazinona sustituido en 3 para incrementar las respuestas sinápticas glutamatergicas - Google Patents
Compuesto [1,2,3]-benzotriazinona sustituido en 3 para incrementar las respuestas sinápticas glutamatergicasInfo
- Publication number
- CU23804B7 CU23804B7 CU20090117A CU20090117A CU23804B7 CU 23804 B7 CU23804 B7 CU 23804B7 CU 20090117 A CU20090117 A CU 20090117A CU 20090117 A CU20090117 A CU 20090117A CU 23804 B7 CU23804 B7 CU 23804B7
- Authority
- CU
- Cuba
- Prior art keywords
- treatment
- glutamatergical
- benzotriazinone
- composite
- replaced
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Esta invención se refiere a la prevención y tratamiento de insuficiencia cerebral, incluyendo incremento del funcionamiento de receptores en la sinapsis en las redes cerebrales responsables de comportamientos de orden superior. Estas redes cerebrales están implicadas en las capacidades cognitivas relacionadas con la alteración de la memoria, tal como se observa en una variedad de demencias y en desequilibrios de la actividad neuronal entre diferentes regiones cerebrales, como se sugiere en trastornos tales como la enfermedad de Parkinson, esquizofrenia y trastornos afectivos. En un aspecto particular, la presente invención se refiere a un compuesto útil para el tratamiento de dichas condiciones y a métodos para utilizar este compuesto para dicho tratamiento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87850307P | 2007-01-03 | 2007-01-03 | |
| US92143307P | 2007-04-02 | 2007-04-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20090117A7 CU20090117A7 (es) | 2011-10-05 |
| CU23804B7 true CU23804B7 (es) | 2012-03-15 |
Family
ID=39608956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20090117A CU23804B7 (es) | 2007-01-03 | 2009-07-03 | Compuesto [1,2,3]-benzotriazinona sustituido en 3 para incrementar las respuestas sinápticas glutamatergicas |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US8173644B2 (es) |
| EP (1) | EP2144506B1 (es) |
| JP (1) | JP5139446B2 (es) |
| CN (1) | CN101616592B (es) |
| AP (1) | AP2502A (es) |
| AR (1) | AR064740A1 (es) |
| AT (1) | ATE527269T1 (es) |
| AU (1) | AU2007342365B2 (es) |
| BR (1) | BRPI0720749A2 (es) |
| CA (1) | CA2674460C (es) |
| CR (1) | CR10906A (es) |
| CU (1) | CU23804B7 (es) |
| CY (1) | CY1112493T1 (es) |
| DK (1) | DK2144506T3 (es) |
| EA (1) | EA017437B1 (es) |
| EC (1) | ECSP099499A (es) |
| ES (1) | ES2374995T3 (es) |
| GE (1) | GEP20125438B (es) |
| GT (1) | GT200900189A (es) |
| HK (1) | HK1140105A1 (es) |
| HN (1) | HN2009001268A (es) |
| HR (1) | HRP20110970T1 (es) |
| IL (1) | IL199651A (es) |
| MA (1) | MA31160B1 (es) |
| ME (1) | ME00819B (es) |
| MX (1) | MX2009007242A (es) |
| MY (1) | MY154877A (es) |
| NI (1) | NI200900131A (es) |
| NZ (1) | NZ578293A (es) |
| PL (1) | PL2144506T3 (es) |
| PT (1) | PT2144506E (es) |
| RS (1) | RS52108B (es) |
| SG (1) | SG163545A1 (es) |
| SI (1) | SI2144506T1 (es) |
| SV (1) | SV2009003322A (es) |
| TN (1) | TN2009000277A1 (es) |
| WO (1) | WO2008085506A1 (es) |
| ZA (1) | ZA200904826B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007342364A1 (en) * | 2007-01-03 | 2008-07-17 | Cortex Pharmaceuticals, Inc. | 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses |
| US8013003B2 (en) | 2007-05-17 | 2011-09-06 | Cortex Pharmaceuticals, Inc. | Di-substituted amides for enhancing glutamatergic synaptic responses |
| SG163526A1 (en) | 2007-08-10 | 2010-08-30 | Cortex Pharma Inc | Bicyclic amides for enhancing glutamatergic synaptic responses |
| US8119632B2 (en) | 2007-08-10 | 2012-02-21 | Cortex Pharmaceuticals, Inc. | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses |
| US20110257186A1 (en) * | 2010-04-15 | 2011-10-20 | Staubli Ursula V | Compositions and methods for treating visual disorders |
| EP2784065B1 (en) | 2011-11-22 | 2016-10-05 | Beijing Medisan Technology Co. Ltd. | Glycine reuptake inhibitor and use thereof |
| FR3019464B1 (fr) * | 2014-04-07 | 2016-05-06 | Servier Lab | Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent |
| FR3034019B1 (fr) * | 2015-03-26 | 2017-03-17 | Servier Lab | Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent |
| AU2016284654B9 (en) | 2015-06-26 | 2020-05-21 | Takeda Pharmaceutical Company Limited | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor |
| CN106226509B (zh) * | 2016-08-12 | 2019-09-06 | 中国人民解放军第四军医大学 | 一种在小鼠前扣带回皮层诱发dse现象的方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3723436A (en) | 1971-02-25 | 1973-03-27 | Sun Oil Co | Process for aromatic lactams |
| DK623586A (da) * | 1985-12-27 | 1987-06-28 | Eisai Co Ltd | Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne |
| FR2597103B1 (fr) | 1986-04-15 | 1988-12-16 | Provesan Sa | Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde |
| ATE215079T1 (de) | 1992-07-24 | 2002-04-15 | Univ California | Arzneimittel, die den durch ampa rezeptoren vermittelten synaptischen respons erhöhen |
| US5962477A (en) * | 1994-04-12 | 1999-10-05 | Adolor Corporation | Screening methods for cytokine inhibitors |
| DE59504622D1 (de) * | 1994-10-31 | 1999-02-04 | Merck Patent Gmbh | Benzylpiperidinderivate mit hoher Affinität zu Bindungsstellen von Aminosäure-Rezeptoren |
| US5650409A (en) | 1995-06-02 | 1997-07-22 | Cortex Pharmaceuticals, Inc. | Benzoyl piperidines/pyrrolidines for enhancing synaptic response |
| US5736543A (en) | 1996-04-03 | 1998-04-07 | The Regents Of The University Of California | Benzoxazines for enhancing synaptic response |
| US6030968A (en) | 1996-09-17 | 2000-02-29 | The Regents Of The University Of California | Positive AMPA receptor modulation to enhance brain neurotrophic factor expression |
| US6110935A (en) * | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
| US5985871A (en) * | 1997-12-24 | 1999-11-16 | Cortex Pharmaceuticals, Inc. | Benzoxazine compounds for enhancing synaptic response |
| HUP0101280A3 (en) | 1998-02-18 | 2003-02-28 | Neurosearch As | Positive ampa receptor modulator compounds and their use |
| US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| US6303542B1 (en) * | 2000-08-18 | 2001-10-16 | Rohm And Haas Company | Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones |
| EA011034B1 (ru) * | 2001-11-26 | 2008-12-30 | Кортекс Фармасеутикалс, Инк. | Соединения карбонилбензоксазина для усиления глутаматергических синаптических ответов |
| JP2003238555A (ja) * | 2002-02-20 | 2003-08-27 | Sumitomo Pharmaceut Co Ltd | 細胞死抑制剤 |
| AUPS255202A0 (en) * | 2002-05-27 | 2002-06-13 | Monash University | Agents and methods for the treatment of disorders associated with motor neuron degeneration |
| KR20050094840A (ko) * | 2003-01-13 | 2005-09-28 | 코텍스 파마슈티칼스, 인크. | 수면 부족 및 스트레스로 인한 인식 저하의 치료방법 |
| GB0317482D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| AU2007342364A1 (en) | 2007-01-03 | 2008-07-17 | Cortex Pharmaceuticals, Inc. | 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses |
| US8013003B2 (en) | 2007-05-17 | 2011-09-06 | Cortex Pharmaceuticals, Inc. | Di-substituted amides for enhancing glutamatergic synaptic responses |
| SG163526A1 (en) | 2007-08-10 | 2010-08-30 | Cortex Pharma Inc | Bicyclic amides for enhancing glutamatergic synaptic responses |
| WO2009038752A2 (en) * | 2007-09-20 | 2009-03-26 | Cortex Pharmaceuticals, Inc. | 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses |
-
2007
- 2007-12-28 SG SG201004695-1A patent/SG163545A1/en unknown
- 2007-12-28 PL PL07868093T patent/PL2144506T3/pl unknown
- 2007-12-28 MX MX2009007242A patent/MX2009007242A/es active IP Right Grant
- 2007-12-28 DK DK07868093.1T patent/DK2144506T3/da active
- 2007-12-28 US US12/448,784 patent/US8173644B2/en active Active
- 2007-12-28 AU AU2007342365A patent/AU2007342365B2/en not_active Ceased
- 2007-12-28 MY MYPI20092796A patent/MY154877A/en unknown
- 2007-12-28 RS RS20110587A patent/RS52108B/en unknown
- 2007-12-28 SI SI200730806T patent/SI2144506T1/sl unknown
- 2007-12-28 NZ NZ578293A patent/NZ578293A/en not_active IP Right Cessation
- 2007-12-28 CN CN2007800508375A patent/CN101616592B/zh not_active Expired - Fee Related
- 2007-12-28 EP EP07868093A patent/EP2144506B1/en active Active
- 2007-12-28 CA CA2674460A patent/CA2674460C/en not_active Expired - Fee Related
- 2007-12-28 PT PT07868093T patent/PT2144506E/pt unknown
- 2007-12-28 EA EA200900925A patent/EA017437B1/ru not_active IP Right Cessation
- 2007-12-28 AT AT07868093T patent/ATE527269T1/de active
- 2007-12-28 GE GEAP200711384A patent/GEP20125438B/en unknown
- 2007-12-28 WO PCT/US2007/026416 patent/WO2008085506A1/en active Application Filing
- 2007-12-28 ME MEP-2009-238A patent/ME00819B/me unknown
- 2007-12-28 JP JP2009544857A patent/JP5139446B2/ja not_active Expired - Fee Related
- 2007-12-28 ES ES07868093T patent/ES2374995T3/es active Active
- 2007-12-28 BR BRPI0720749-2A patent/BRPI0720749A2/pt not_active Application Discontinuation
- 2007-12-28 ZA ZA200904826A patent/ZA200904826B/xx unknown
- 2007-12-28 AP AP2009004931A patent/AP2502A/xx active
-
2008
- 2008-01-03 AR ARP080100022A patent/AR064740A1/es not_active Application Discontinuation
-
2009
- 2009-06-30 TN TNP2009000277A patent/TN2009000277A1/fr unknown
- 2009-07-01 NI NI200900131A patent/NI200900131A/es unknown
- 2009-07-02 SV SV2009003322A patent/SV2009003322A/es unknown
- 2009-07-02 IL IL199651A patent/IL199651A/en active IP Right Grant
- 2009-07-02 GT GT200900189A patent/GT200900189A/es unknown
- 2009-07-02 CR CR10906A patent/CR10906A/es not_active Application Discontinuation
- 2009-07-03 CU CU20090117A patent/CU23804B7/es active IP Right Grant
- 2009-07-03 HN HN2009001268A patent/HN2009001268A/es unknown
- 2009-07-07 EC EC2009009499A patent/ECSP099499A/es unknown
- 2009-07-31 MA MA32135A patent/MA31160B1/fr unknown
-
2010
- 2010-06-29 HK HK10106349.3A patent/HK1140105A1/xx not_active IP Right Cessation
-
2011
- 2011-12-23 HR HR20110970T patent/HRP20110970T1/hr unknown
- 2011-12-28 CY CY20111101287T patent/CY1112493T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU23804B7 (es) | Compuesto [1,2,3]-benzotriazinona sustituido en 3 para incrementar las respuestas sinápticas glutamatergicas | |
| TN2009000278A1 (en) | 3-substituted-[1,2,3] benzotriazinone compounds for enhancing glutamatergic synaptic responses | |
| DOP2018000204A (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| CL2013001073A1 (es) | Compuestos derivados de 6-amino-nicotinamidas sustituidas, como moduladores de kcnq2/3; composicion farmaceutica que los comprende, util para el tratamiento y/o profilaxis de trastornos y/o enfermedades seleccionadas de dolor, epilepsia, ansiedad, enfermedades cognitivas, entre otras. | |
| CR20130339A (es) | Nuevos derivados heterocíclicos y su uso en el tratamiento de desordenes neurológicos | |
| ECSP12011908A (es) | OCTAHIDROPIRROLO[3,4-c]PIRROLOS DISUSTITUIDOS COMO | |
| EA201401350A1 (ru) | Бензимидазолы, модулирующие tnf-альфа | |
| BRPI0919920A2 (pt) | compostos para tratamento de doenças e desordens oftálmicas | |
| CL2009000990A1 (es) | Uso de epotilona d para el tratamiento de enfermedades asociadas a tau, tal como enfermedad alzheimer, parkinson, entre otras. | |
| CL2014002334A1 (es) | Compuestos derivados de indanos espirofusionados, inhibidores de la beta-secretasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como deterioro cognitivo, trastornos neurodegenerativos, demencia, entre otras. | |
| BR112014004306A2 (pt) | fotossensibilizadores de (bacterio)clorofila para tratamento de doenças e distúrbios do olho | |
| BRPI0917440A2 (pt) | composições farmacêuticas oftálmicas para o tratamento de patologias neoangiogênicas do olho | |
| CL2012003212A1 (es) | Formas cristalinas i y ii de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida monohidratado; procedimientos de preparacion; composicion farmaceutica; su procedimiento de preparacion; y su uso para el tratamiento de trastornos tales como trastorno por deficit de atencion y enfermedad de parkinson. | |
| ECSP11010956A (es) | Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos | |
| WO2013029060A3 (en) | Compositions and methods for treating neurodegenerative disease | |
| EP2750606A4 (en) | METHOD FOR THE DIAGNOSIS AND TREATMENT OF NEUROLOGICAL AND NEURODEEGENERATIVE DISEASES, DISORDERS AND RELATED METHODS | |
| UY34991A (es) | Inhibidores de la beta-secretasa | |
| BR112013018296A2 (pt) | tratamento de disfunções cognitivas em esquizofrenia | |
| BR0214425A (pt) | Compostos carbonilbenzoxazina para aperfeiçoamento de respostas sinápticas glutamatérgicas | |
| CL2007003719A1 (es) | Compuestos derivados de espiro-piperidina, moduladores del receptor de vasopresina v1a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como dismenorrea, hipertension, ansiedad y trastornos depresivos. | |
| DE602008004563D1 (de) | Carbonylamino-derivate zur behandlung von entzündlicher darmerkrankung | |
| UA93306C2 (ru) | Соединение 3-замещенного-[1,2,3]-бензотриазинона для улучшения глутаматергических синаптических реакций | |
| BR112012004988A2 (pt) | compostos para tratar transtornos ou doenças associadas com atividade do receptor de neuroquinina 2 | |
| CL2018001633A1 (es) | Composiciones de benzofenonas polihidroxiladas y métodos para el tratamiento de trastornos neurodegenerativos | |
| GT200900150A (es) | Nuevos compuestos azabiciclicos, un proceso para su preparacion y las composiciones farmaceuticas que los contienen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant of patent |